Cereno Scientific releases Biostock interview with CEO Sten R. Sörensen on Expanded Access being approved by the FDA
Cereno Scientific (Nasdaq First North: CRNO B) today announced that a video interview by Biostock has been released with CEO Sten R. Sörensen, commenting on the approval by the FDA of an Expanded Access Program, sometimes called “Compassionate Use”, to Cereno’s investigational drug CS1 for use in an extension of the ongoing Phase II trial evaluating CS1 in the rare disease pulmonary arterial hypertension (PAH). Watch here: Cereno Scientific's PAH drug candidate granted "Compassionate Use" (youtube.com) “This is an important milestone on our